Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.
In his second "Executive Decision" segment, Cramer again welcomed Dr. Leonard Schleiffer, president and CEO of Regeneron Pharmaceuticals (REGN) , to the show. Shares of Regeneron are off 25% from their peak in June.
Schleiffer said that it's rare to be able to change the way medicine gets done, but Regeneron is fortunate to have a robust pipeline of drugs with many prospects for doing just that. His company currently has 11 drugs in Phase I testing, six in Phase II and five in Phase III.
Schleiffer said that Dupixent, a twice-monthly injection for eczema, could have multiple indications including asthma, nasal polyps and possibly even food allergies. Regeneron is also working on immunotherapy treatments for skin cancer that are also promising.
As for the threat of competition for Regeneron's lead product, Eylea, Schleiffer said it's a high bar for others to match. Elyea, used to treat certain retina diseases, currently has two million injections a year, he said, while the competition may still be years away from having a single injection.
Over on Real Money, Cramer says General Electric (GE) really owes us an explanation now. Get more on his insights with a free trial subscription to Real Money.
Cramer and the AAP team have the highlights from their November members-only call. Find out what they're telling their investment club members about Allergan, (AGN) , Apache Corp. (APA) and more -- and get in on the conversation with a free trial subscription to Action Alerts PLUS.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To read a full recap of this episode of "Mad Money," click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
More of What's Trending on TheStreet: